DoD Drug & Vacc Ad

Abstract

This Project funds development of candidate medical countermeasures for endemic infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices. These funds support human clinical effectiveness (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works and continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and accelerated recovery time once diagnosed to enhance battlefield readiness. All clinical trials are conducted in accordance with United States (U.S.) Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production). Products from this Project will transition to PE 0604807A/Project 849 at MS B.

Document Details

• Document Type: Project
• Publication Date: Oct 01, 2024
• Source ID: 808_0603807A_4_2040_PB_2024

Tags

Fields of Study

• Medicine

Readers

• Infectious Disease/Epidemiology
• Military Science and Technology Research and Modernization.

Technology Areas

• Biotechnology